col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


76 Results       Page 1

 [1] 
American Chemical Society: ACS Pharmacology & Translational Science
  original article Date Title Authors   All Authors
1 [GO] 2024―Oct―04 Thiol-Reactive or Redox-Active: Revising a Repurposing Screen Led to a New Invalidation Pipeline and Identified a True Noncovalent Inhibitor Against Papain-like Protease from SARS-CoV-2 Maria Kuzikov, Stefano Morasso, Jeanette Reinshagen, Markus Wolf, Vittoria Monaco, Flora Cozzolino, et al. (+13)
2 [GO] 2024―Oct―02 Novel Alkynylamide-Based Nonpeptidic Allosteric Inhibitors for SARS-CoV-2 3-Chymotrypsin-like Protease Jian Xue, Hongtao Li, Ruyu Wang, Meiting Wang, Xixiang Chen, Yaqi Deng, et al. (+7)
3 [GO] 2024―Sep―12 Evaluation of Angiotensin-Converting Enzyme 2 Expression In Vivo with Novel 68Ga-Labeled Peptides Originated from the Coronavirus Receptor-Binding Domain Linlin Li, Rongxi Wang, Li He, Hua Guo, Lei Fu, Guochang Wang, et al. (+9)
4 [GO] 2024―Mar―21 Screening Peptide Drug Candidates To Neutralize Whole Viral Agents: A Case Study with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Cemile Elif Özçelik, Cemre Zekiye Araz, Özgür Yılmaz, Sevgi Gülyüz, Pınar Özdamar, Ezgi Salmanlı, et al. (+2)
5 [GO] 2024―Mar―06 Correction to “Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity” Philipp Flury, Julian Breidenbach, Nadine Krüger, Rabea Voget, Laura Schäkel, Yaoyao Si, et al. (+15)
6 [GO] 2024―Feb―01 Neutralization of SARS-CoV-2 and Intranasal Protection of Mice with a nanoCLAMP Antibody Mimetic Quentin Pagneux, Nathalie Garnier, Manon Fabregue, Sarah Sharkaoui, Sophie Mazzoli, Ilka Engelmann, et al. (+7)
7 [GO] 2024―Jan―19 Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity Philipp Flury, Julian Breidenbach, Nadine Krüger, Rabea Voget, Laura Schäkel, Yaoyao Si, et al. (+15)
8 [GO] 2024―Jan―16 Methotrexate Inhibits the Binding of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Receptor Binding Domain to the Host-Cell Angiotensin-Converting Enzyme-2 (ACE-2) Receptor Soo-Kyung Kim, Sartanee Suebka, Adley Gin, Phuong-Diem Nguyen, Yisha Tang, Judith Su, William A. Goddard
9 [GO] 2023―Dec―13 Levels of Angiotensin and Kinin Metabolite Peptides Related to COVID-19 Severity Ben K. Ahiadu, Ami Grunbaum, Nicholas Rozza, Richard B. Kremer, James F. Rusling
10 [GO] 2023―Sep―06 Emerging Landscape of Preclinical Models for Studying COVID-19 Neurologic Diseases Jason Li, Jing Wang, Hu Wang
11 [GO] 2023―Aug―04 Deuremidevir and Simnotrelvir-Ritonavir for the Treatment of COVID-19 Ke-Wei Zhu
12 [GO] 2023―Jul―03 Messenger RNA-Based Therapeutics and Vaccines: What’s beyond COVID-19? Dongqiao Li, Cynthia Liu, Yingzhu Li, Rumiana Tenchov, Janet M. Sasso, Di Zhang, et al. (+4)
13 [GO] 2023―Jun―05 Emerging Landscape of Nanobodies and Their Neutralizing Applications against SARS-CoV-2 Virus Xuemei Feng, Hu Wang
14 [GO] 2023―May―22 Engineering an ACE2-Derived Fragment as a Decoy for Novel SARS-CoV-2 Virus Fabiana Renzi, Austin Seamann, Koelina Ganguly, Kabita Pandey, Siddappa N. Byrareddy, Surinder Batra, et al. (+2)
15 [GO] 2023―Mar―07 Drug-Repurposing Screening Identifies a Gallic Acid Binding Site on SARS-CoV-2 Non-structural Protein 7 Yushu Gu, Miaomiao Liu, Bart L. Staker, Garry W. Buchko, Ronald J. Quinn
16 [GO] 2023―Feb―27 Association of COVID-19 with Comorbidities: An Update Sayan Chatterjee, Lakshmi Vineela Nalla, Monika Sharma, Nishant Sharma, Aditya A. Singh, Fehmina Mushtaque Malim, et al. (+6)
17 [GO] 2022―Dec―28 Broad-Spectrum Cyclopropane-Based Inhibitors of Coronavirus 3C-like Proteases: Biochemical, Structural, and Virological Studies Chamandi S. Dampalla, Harry Nhat Nguyen, Athri D. Rathnayake, Yunjeong Kim, Krishani Dinali Perera, Trent K. Madden, et al. (+8)
18 [GO] 2022―Dec―23 Detailed Insights into the Inhibitory Mechanism of New Ebselen Derivatives against Main Protease (Mpro) of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Pritiranjan Sahoo, Dipti Ranjan Lenka, Monojit Batabyal, Pritam Kumar Pain, Sangit Kumar, Debasish Manna, Atul Kumar
19 [GO] 2022―Jun―22 Enzyme Nanoscale Interactions with Manganese Zinc Sulfide Give Insight into Potential Antiviral Mechanisms and SARS-CoV-2 Inhibition Robert K. DeLong, Hanah Huber, Cesar Aparicio-Lopez, Abeera Bhatti, Ryan Swanson, Tej B. Shrestha, Natasha N. Gaudreault
20 [GO] 2022―May―23 Different Aspects of Emetine’s Capabilities as a Highly Potent SARS-CoV-2 Inhibitor against COVID-19 Mehdi Valipour
21 [GO] 2022―Apr―04 Hit Expansion of a Noncovalent SARS-CoV-2 Main Protease Inhibitor Jens Glaser, Ada Sedova, Stephanie Galanie, Daniel W. Kneller, Russell B. Davidson, Elvis Maradzike, et al. (+12)
22 [GO] 2022―Apr―01 Natural Compounds Inhibit SARS-CoV-2 nsp13 Unwinding and ATPase Enzyme Activities Angela Corona, Krzysztof Wycisk, Carmine Talarico, Candida Manelfi, Jessica Milia, Rolando Cannalire, et al. (+8)
23 [GO] 2022―Feb―14 Allosteric Site of ACE-2 as a Drug Target for COVID-19 Kunal Dutta
24 [GO] 2022―Jan―25 Experimental Model of Pulmonary Inflammation Induced by SARS-CoV-2 Spike Protein and Endotoxin Manoj Puthia, Lloyd Tanner, Ganna Petruk, Artur Schmidtchen
25 [GO] 2022―Jan―24 Validation and Invalidation of SARS-CoV-2 Papain-like Protease Inhibitors Chunlong Ma, Jun Wang
26 [GO] 2022―Jan―03 SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening Kirill Gorshkov, Desarey Morales Vasquez, Kevin Chiem, Chengjin Ye, Bruce Nguyen Tran, Juan Carlos de la Torre, et al. (+4)
27 [GO] 2021―Sep―17 Hybrid In Silico Approach Reveals Novel Inhibitors of Multiple SARS-CoV-2 Variants Sankalp Jain, Daniel C. Talley, Bolormaa Baljinnyam, Jun Choe, Quinlin Hanson, Wei Zhu, et al. (+9)
28 [GO] 2021―Sep―06 Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 Replication by Hypertonic Saline Solution in Lung and Kidney Epithelial Cells Rafael R. G. Machado, Talita Glaser, Danielle B. Araujo, Lyvia Lintzmaier Petiz, Danielle B. L. Oliveira, Giuliana S. Durigon, et al. (+6)
29 [GO] 2021―Jul―29 Identification of Novel Neutralizing Monoclonal Antibodies against SARS-CoV-2 Spike Glycoprotein Devivasha Bordoloi, Ziyang Xu, Michelle Ho, Mansi Purwar, Pratik Bhojnagarwala, Joel Cassel, et al. (+18)
30 [GO] 2021―Jun―09 Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir Zilei Xia, Michael Sacco, Yanmei Hu, Chunlong Ma, Xiangzhi Meng, Fushun Zhang, et al. (+4)
31 [GO] 2021―Apr―29 Correction to “Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir” Ting Chen, Cheng-Yin Fei, Yi-Ping Chen, Karen Sargsyan, Jian-Jong Liang, Chun-Che Liao, et al. (+4)
32 [GO] 2021―Apr―16 Identification of Novel MicroRNAs Targeting SARS-CoV-2 through the Regulation of TMPRSS2/PI3K/AKT/PTEN Alignment in Lung Cancer: An in Silico Analysis Debasmita Mukhopadhyay, Nour AlSawaftah, Ghaleb A Husseini
33 [GO] 2021―Apr―02 Discovery of TMPRSS2 Inhibitors from Virtual Screening as a Potential Treatment of COVID-19 Xin Hu, Jonathan H. Shrimp, Hui Guo, Miao Xu, Catherine Z. Chen, Wei Zhu, et al. (+6)
34 [GO] 2021―Mar―26 Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir Ting Chen, Cheng-Yin Fei, Yi-Ping Chen, Karen Sargsyan, Chun-Ping Chang, Hanna S. Yuan, Carmay Lim
35 [GO] 2021―Mar―22 Repurposing Quinoline and Artemisinin Antimalarials as Therapeutics for SARS-CoV-2: Rationale and Implications Tessa M. Firestone, Opeoluwa O. Oyewole, St Patrick Reid, Caroline L. Ng
36 [GO] 2021―Mar―19 COVID-19: Is There a Link between Alcohol Abuse and SARS-CoV-2-Induced Severe Neurological Manifestations? Jibran Sualeh Muhammad, Ruqaiyyah Siddiqui, Naveed Ahmed Khan
37 [GO] 2021―Mar―17 A Blueprint for High Affinity SARS-CoV-2 Mpro Inhibitors from Activity-Based Compound Library Screening Guided by Analysis of Protein Dynamics Jonas Gossen, Simone Albani, Anton Hanke, Benjamin P. Joseph, Cathrine Bergh, Maria Kuzikov, et al. (+14)
38 [GO] 2021―Mar―11 Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, et al. (+27)
39 [GO] 2021―Mar―04 COVID-19: Does SARS-CoV-2 Modulate Acanthamoeba Epigenetics to Enhance Survival and Transmission in the Environment? Jibran Sualeh Muhammad, Ruqaiyyah Siddiqui, Naveed Ahmed Khan
40 [GO] 2021―Mar―01 Toward the Next-Generation COVID-19 Vaccines That Circumvent Antigenic Drift while Defusing Viral Infection Ariel Fernández
41 [GO] 2021―Feb―05 SARS-CoV-2 Glycosylation Suggests That Vaccines Should Have Adopted the S1 Subunit as Antigen Ariel Fernández
42 [GO] 2021―Jan―29 Docking Prediction of Levodopa in the Receptor Binding Domain of Spike Protein of SARS-CoV-2 Abdul Mannan Baig, Areeba Khaleeq, Hira Syeda, Noor Bibi
43 [GO] 2021―Jan―21 Glycosylation of SARS-CoV-2 Steers Evolutionary Outcomes in the Postvaccination Phase Ariel Fernández
44 [GO] 2021―Jan―15 Diagnostic, Prognostic, and Therapeutic Use of Radiopharmaceuticals in the Context of SARS-CoV-2 Roger M. Pallares, Rebecca J. Abergel
45 [GO] 2021―Jan―10 SARS-CoV-2, Hypoxia, and Calcium Signaling: The Consequences and Therapeutic Options Chhanda Charan Danta
46 [GO] 2020―Dec―31 COVID-19 Evolution in the Post-Vaccination Phase: Endemic or Extinct? Ariel Fernández
47 [GO] 2020―Dec―30 Innate Immunity Plays a Key Role in Controlling Viral Load in COVID-19: Mechanistic Insights from a Whole-Body Infection Dynamics Model Prashant Dogra, Javier Ruiz-Ramírez, Kavya Sinha, Joseph D. Butner, Maria J. Peláez, Manmeet Rawat, et al. (+6)
48 [GO] 2020―Dec―29 Antibacterial and Antiviral Functional Materials: Chemistry and Biological Activity toward Tackling COVID-19-like Pandemics Bhuvaneshwari Balasubramaniam, Sudhir Ranjan, Mohit Saraf, Prasenjit Kar, Surya Pratap Singh, Vijay Kumar Thakur, et al. (+2)
49 [GO] 2020―Dec―12 Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial Leticia R. Cruz, Idania Baladrón, Aliusha Rittoles, Pablo A. Díaz, Carmen Valenzuela, Raúl Santana, et al. (+19)
50 [GO] 2020―Dec―09 Identification of Novel MicroRNAs as Promising Therapeutics for SARS-CoV-2 by Regulating the EGFR-ADAM17 Axis: An In Silico Analysis Debasmita Mukhopadhyay, Nour AlSawaftah, Ghaleb A. Husseini
51 [GO] 2020―Dec―01 Clinically Approved Antiviral Drug in an Orally Administrable Nanoparticle for COVID-19 Bapurao Surnar, Mohammad Z. Kamran, Anuj S. Shah, Shanta Dhar
52 [GO] 2020―Nov―17 Targeting ACE2-RBD Interaction as a Platform for COVID-19 Therapeutics: Development and Drug-Repurposing Screen of an AlphaLISA Proximity Assay Quinlin M. Hanson, Kelli M. Wilson, Min Shen, Zina Itkin, Richard T. Eastman, Paul Shinn, Matthew D. Hall
53 [GO] 2020―Nov―11 Clinical HDAC Inhibitors Are Effective Drugs to Prevent the Entry of SARS-CoV2 Ke Liu, Rongfeng Zou, Wenqiang Cui, Meiqing Li, Xueying Wang, Junlin Dong, et al. (+8)
54 [GO] 2020―Nov―07 Probing the Dynamic Structure-Function and Structure-Free Energy Relationships of the Coronavirus Main Protease with Biodynamics Theory Hongbin Wan, Vibhas Aravamuthan, Robert A. Pearlstein
55 [GO] 2020―Nov―03 Docking Prediction of Amantadine in the Receptor Binding Domain of Spike Protein of SARS-CoV-2 Abdul Mannan Baig, Areeba Khaleeq, Hira Syeda
56 [GO] 2020―Oct―19 Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles Catherine Z. Chen, Miao Xu, Manisha Pradhan, Kirill Gorshkov, Jennifer D. Petersen, Marco R. Straus, et al. (+9)
57 [GO] 2020―Oct―15 Defusing SARS-CoV-2: Emergency Brakes in a Vaccine Failure Scenario Ariel Fernández
58 [GO] 2020―Oct―14 Virtual and In Vitro Antiviral Screening Revive Therapeutic Drugs for COVID-19 Giovanni Bocci, Steven B. Bradfute, Chunyan Ye, Matthew J. Garcia, Jyothi Parvathareddy, Walter Reichard, et al. (+7)
59 [GO] 2020―Oct―09 Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors Chunlong Ma, Yanmei Hu, Julia Alma Townsend, Panagiotis I. Lagarias, Michael Thomas Marty, Antonios Kolocouris, Jun Wang
60 [GO] 2020―Oct―09 Development of a High-Throughput Homogeneous AlphaLISA Drug Screening Assay for the Detection of SARS-CoV-2 Nucleocapsid Kirill Gorshkov, Catherine Z. Chen, Miao Xu, Juan Carlos de la Torre, Luis Martinez-Sobrido, Thomas Moran, Wei Zheng
61 [GO] 2020―Sep―30 Helminths and COVID-19 Co-Infections: A Neglected Critical Challenge Amir Abdoli
62 [GO] 2020―Sep―28 Ivermectin, Famotidine, and Doxycycline: A Suggested Combinatorial Therapeutic for the Treatment of COVID-19 Parth Sarthi Sen Gupta, Malay Kumar Rana
63 [GO] 2020―Sep―28 Heme/Hemeoxygenase-1 System Is a Potential Therapeutic Intervention for COVID-19 Patients with Severe Complications Biplab K Maiti
64 [GO] 2020―Sep―18 SARS-CoV-2 vaccine development: An overview and perspectives Yi Liu, Kai Wang, Tarik F. Massoud, Ramasamy Paulmurugan
65 [GO] 2020―Sep―15 Achilles’ Heel of SARS-CoV-2 Structure Ariel Fernández
66 [GO] 2020―Sep―08 Can SARS-CoV-2 Accumulate Mutations in the S-Protein to Increase Pathogenicity? Aditya K. Padhi, Timir Tripathi
67 [GO] 2020―Sep―07 An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19 Jonathan H. Shrimp, Stephen C. Kales, Philip E. Sanderson, Anton Simeonov, Min Shen, Matthew D. Hall
68 [GO] 2020―Sep―04 Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening Wei Zhu, Miao Xu, Catherine Z. Chen, Hui Guo, Min Shen, Xin Hu, et al. (+4)
69 [GO] 2020―Sep―01 Therapeutically Targeted Destabilization of the Quaternary Structure of the Spike Protein in the Dominant G614 Strain of SARS-CoV-2 Ariel Fernández
70 [GO] 2020―Aug―27 Double-Barreled CRISPR Technology as a Novel Treatment Strategy For COVID-19 Dhanusha Nalawansha, Kusal Samarasinghe
71 [GO] 2020―Aug―18 Dipeptidyl Peptidase-4: A Potential Therapeutic Target in Diabetic Kidney Disease with SARS-CoV-2 Infection Chhanda Charan Danta
72 [GO] 2020―Aug―04 Can Papain-like Protease Inhibitors Halt SARS-CoV-2 Replication? Biplab K Maiti
73 [GO] 2020―Jul―30 Potential therapeutic agents and associated bioassay data for COVID-19 and related human coronavirus infections Qiongqiong Zhou, Junko Kato-Weinstein, Yingzhu Li, Yi Deng, Roger Granet, Linda Garner, et al. (+4)
74 [GO] 2020―Jul―24 Potential Role of Peptide-Based Antiviral Therapy Against SARS-CoV-2 Infection Biplab K. Maiti
75 [GO] 2020―Jul―23 SARS-CoV-2 receptor ACE2 is enriched in a subpopulation of mouse tongue epithelial cells in non-gustatory papillae, but not in taste buds or embryonic oral epithelium Zhonghou Wang, Jingqi Zhou, Brett Marshall, Romdhane Rekaya, Kaixiong Ye, Hong-Xiang Liu
76 [GO] 2020―Jun―16 The Potential of Antimicrobial Peptides as an Antiviral Therapy against COVID-19 Sherif Elnagdy, Maha AlKhazindar
 [1] 

76 Results       Page 1


[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.011 sec